RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc. (RTI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: RTI designs, manufactures, and markets patented safety medical products, primarily the VanishPoint® retractable syringe, to prevent needlestick injuries. The company operates in a market dominated by Becton Dickinson (BD), against which RTI is engaged in ongoing patent and antitrust litigation. RTI relies heavily on a single Chinese manufacturer, Double Dove, for approximately 64% of its finished product supply.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 7.1% to $36.2 million, primarily due to the expiration of a significant Department of Health and Human Services (DHHS) contract for swine flu vaccinations that boosted 2009 revenues.
• Turnaround to Profitability: The company reported a net income of $2.4 million in 2010, reversing a $9.4 million net loss in 2009. This was driven by a $9.3 million gain from litigation settlements and fee waivers, alongside a 28.4% reduction in operating expenses.
• Expense Reduction: Operating expenses dropped significantly due to lower litigation costs (approx. $5.1 million less than 2009) following a fee-capping agreement with counsel, and reduced compensation costs.
• Liquidity Improvement: Cash and cash equivalents increased by $5.1 million (28.4%) to $23.3 million, bolstered by litigation proceeds and improved cash flow from operations ($8.7 million).

Guidance, Outlook, Risks, and Unusual Items

Unusual Items

• Litigation Settlements: RTI recognized $9.3 million in "Litigation settlements, net." This included $6 million received from Abbott Laboratories and Hospira, a $1.4 million waiver of marketing fees by Abbott, and a $2 million option fee payment from Hospira.
• Impairment Charges: The company recorded $365,000 in impairment charges for R&D equipment in 2010, compared to $2.6 million in 2009.

Outlook and Management Commentary

• Market Access: Management continues to face barriers to market entry due to exclusive contracts held by competitor BD. The company relies on litigation and international sales growth to offset domestic restrictions.
• Future Cash Flow: RTI expects to receive an additional $6 million from Hospira in 2011 related to the licensing option agreement.
• Cost Management: The company plans to continue cost-cutting measures and has recently purchased molding machines to expand in-house production capabilities.

Risks and Contingencies

• Patent Litigation: A favorable judgment against BD regarding patent infringement is currently stayed pending appeal. A final appellate decision is expected in 2011. Separate antitrust claims against BD are scheduled for trial in January 2012.
• Supplier Concentration: Approximately 64.1% of finished products are sourced from Double Dove in China. Disruption of this supply chain could impact specific product lines (0.5mL, 5mL, 10mL syringes).
• Patent Expiration: Principal U.S. patents protecting the core technology are scheduled to expire in May 2015.
• Stock Price: The low stock price ($1.61 as of March 1, 2011) poses a risk of delisting from the NYSE Amex if a reverse split is not executed.

Investor Verification Checklist

• Litigation Status: Verify the outcome of the BD patent appeal and the timeline for the antitrust trial, as these are critical to future market access and potential damages.
• Settlement Proceeds: Confirm the receipt of the remaining $6 million in option payments from Hospira scheduled for 2011.
• Supply Chain Resilience: Assess the company's contingency plans for the 0.5mL, 5mL, and 10mL syringes if the relationship with Double Dove is disrupted.
• Preferred Stock Obligations: Review the $13.6 million in preferred dividends in arrears and the impact on common shareholder distributions.
• Patent Portfolio: Evaluate the status of new patent applications intended to extend protection beyond the May 2015 expiration of current core patents.